Research at the interface of optical and ionizing radiation for innovative cancer imaging and therapy

用于创新癌症成像和治疗的光学和电离辐射界面研究

• 批准号: 9115570
• 负责人: Simon R Cherry
• 金额: $ 71.23万
• 依托单位: UNIVERSITY OF CALIFORNIA AT DAVIS
• 依托单位国家: 美国
• 财政年份: 2015
• 资助国家: 美国
• 起止时间: 2015-08-01 至 2022-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9115570
• 关键词: Animal Model; Area; Biological Assay; Cancer Biology; Cancer Patient; Detection; Development; Diagnosis; Diagnostic Neoplasm Staging; Disease; Dose; Environment; Evaluation; Excision; Feedback; Foundations; Generations; Goals; Health; Image; Imaging technology; Investments; Ionizing radiation; Laboratories; Light; Link; Malignant Neoplasms; Methods; Molecular; Noise; Operative Surgical Procedures; Optics; Patient Monitoring; Patients; Photons; Phototherapy; Play; Positron-Emission Tomography; Radiation; Radioisotopes; Research; Resolution; Role; Safety; Science; Signal Transduction; Source; Staging; Surgeon; Testing; Therapeutic; Time; Ultrasonography; Work; anticancer research; base; bioimaging; cancer imaging; cancer therapy; cost; detector; fight against; imaging biomarker; imaging modality; improved; in vivo; innovation; instrument; invention; luminescence; molecular imaging; novel strategies; novel therapeutic intervention; optical imaging; photonics; preclinical study; programs; radiotracer; screening; targeted delivery; targeted treatment; theranostics; tool; treatment planning; tumor

 DESCRIPTION (provided by applicant): Imaging is often fundamental to screening, detection, diagnosis and staging of cancer. It also plays significant roles in cancer treatment planning, and in monitoring patients during and after therapy. Imaging also is a vital tool in cancer research, where it is used to improve our understanding of cancer biology and in the longitudinal evaluation of the effects of new therapeutic strategies in preclinical studies. Further development of existing imaging technologies, as well as the invention or discovery of new ones, is critical in the fight against cancer. Improvements in imaging technologies will help us detect disease earlier, stage cancer more accurately, select more appropriate treatments and provide earlier feedback when a treatment is not working. Imaging will become further engrained in interventional cancer therapies, especially in surgery where there is an urgent need for better methods to guide surgeons during resection to avoid functional areas and achieve cancer-free margins wherever possible. We also expect imaging research to enhance cancer imaging through faster and lower cost imaging, and by reducing radiation dose, thus making imaging more widely accessible, and enhancing patient comfort and safety. In the laboratory setting, instruments capable of improved structural, functional and molecular characterization of tumors in appropriate animal models, as well as the development of new imaging biomarkers, often linked with targeted therapies, will be critical in providing the foundation for these advances. Thus further investments in cancer imaging at all levels are likely to yield a high pay off. Molecular imaging with optical contrast or radiotracers provides some of the highest sensitivity in vivo assays available, and offers a rich source of contrast mechanisms. In this proposal we build on our 25-year track record in the field of biomedical imaging and propose to exploit new opportunities for cancer imaging and cancer theranostics that lie at the intersection of photonics and radiation science. We propose initial projects that 1) offer the prospect of high-resolution optical imaging of radionuclides using ultrasound-modulation of Cerenkov luminescence; 2) enable targeted delivery of light to tumors deep inside the body allowing phototherapy to be applied as a systemic treatment for metastatic disease and 3) exploit the instantaneous generation of optical Cerenkov photons in positron emission tomography (PET) detectors with the goal of significantly improving the timing resolution and the signal-to-noise ratio in PET imaging. The approach in this proposal is to create and support a research environment that allows our laboratory to rapidly test and develop new ideas, with a goal of efficiently developing innovative cancer imaging and therapeutic strategies that will either directly (through improved diagnosis, staging or therapy), or indirectly (via contributions o cancer research) benefit cancer patients.

 描述（通过应用程序提供）：成像通常是癌症筛查，检测，诊断和分期的基础。它在癌症治疗计划中以及在治疗期间和之后监测患者中也起着重要作用。成像也是癌症研究中的重要工具，它用于提高我们对癌症生物学的理解以及对临床前研究中新治疗策略的影响的纵向评估。现有成像技术的进一步开发以及发明或发现新成像技术对于打击癌症至关重要。成像技术的改进将有助于我们更早发现疾病，更准确地进行癌症，选择更合适的治疗方法，并在治疗不起作用时提供早期的反馈。成像将进一步参与介入癌症疗法，尤其是在迫切需要在切除过程中指导外科医生以避免功能区域并尽可能实现无癌边缘的手术。我们还期望成像研究通过更快，更低的成本成像来增强癌症成像，并减少辐射剂量，从而使成像更广泛地访问，并增强患者的舒适性和安全性。在实验室环境中，能够改善适当动物模型中肿瘤的结构，功能和分子表征的仪器以及通常与靶向疗法有关的新成像生物标志物的开发对于为这些进步奠定基础至关重要。在各个级别上，对癌症成像的进一步投资可能会带来高的回报。具有光学对比度或放射性示例的分子成像提供了体内鉴定的一些最高灵敏度，并提供了丰富的对比度机制。在这项建议中，我们以生物医学成像领域的25年历史记录以及提案，以利用位于光子学和放射科学交集的癌症成像和癌症疗法的新机会。我们提出的初始项目1）提供了使用Cerenkov发光的超声调节对放射线的高分辨率光学成像的前景； 2）将有针对性的光递送到体内深处的肿瘤中，可以将光疗作为用于转移性疾病的系统治疗，3）利用阳性发射断层扫描（PET）探测器中的光学cerenkov照片的瞬时生成，目的是显着改善了定时分辨率和信号到宠物的信号到宠物的比率。该提案中的方法是创建和支持一个研究环境，该研究环境使我们的实验室能够快速测试和发展新的想法，其目的是有效地开发创新的癌症成像和治疗策略，该策略将直接（通过改进的诊断，分期或治疗）或秘密地（通过促进）（通过贡献O癌症研究）对癌症患者有益于癌症患者。